Page 99 - TD-4-1

Tumor Discovery Identification of a potential KRAS(G12C) inhibitor

11. Smalley KS, Lioni M, Noma K, et al. In vitro three- Pharmacophoric analogs of sotorasib-entrapped KRAS
dimensional tumor microenvironment models for G12C in its inactive GDP-bound conformation: Covalent
anticancer drug discovery. Expert Opin Drug Discov. docking and molecular dynamics investigations. Mol Divers.
2008;3:1-10. 2023;27:1795-1807.
doi: 10.1517/17460441.3.1.1 doi: 10.1007/s11030-022-10534-1
12. Downward J. Targeting RAS signalling pathways in cancer 24. Mortier J, Friberg A, Badock V, et al. Computationally
therapy. Nat Rev Cancer. 2003;3:11-22. empowered workflow identifies novel covalent allosteric
binders for KRAS G12C . ChemMedChem. 2020;15:827-832
doi: 10.1038/nrc969
doi: 10.1002/cmdc.201900727
13. Kim HJ, Lee HN, Jeong MS, et al. Oncogenic KRAS: Signaling
and drug resistance. Cancers (Basel). 2021;13:5599. 25. Nnadi CI, Jenkins ML, Gentile DR, et al. Novel K-Ras G12C
switch-II covalent binders destabilize ras and accelerate
doi: 10.3390/cancers13225599 nucleotide exchange. J Chem Inf Model. 2018;58:464-471.
14. Singh G, Thakur N, Kumar U. RAS: Circuitry and therapeutic doi: 10.1021/acs.jcim.7b00399
targeting. Cell Signal. 2023;101:110505.
26. Boehm M, Wu TY, Haussen H, et al. Similarity searching and
doi: 10.1016/j.cellsig.2022.110505 scaffold hopping in synthetically accessible combinatorial
15. Ferrer I, Zugazagoitia J, Herbertz S, et al. KRAS-Mutant chemistry spaces. J Med Chem. 2008;51:2468-2480.
non-small cell lung cancer: From biology to therapy. Lung doi: 10.1021/jm0707727
Cancer. 2018;124:53-64.
27. Madhavi Sastry G, Adzhigirey M, Day T, et al. Protein and
doi: 10.1016/j.lungcan.2018.07.013 ligand preparation: Parameters, protocols, and influence on
16. Ciardiello D, Maiorano BA, Martinelli E. Targeting KRAS G12C virtual screening enrichments. J Comput Aided Mol Des.
in colorectal cancer: The beginning of a new era. ESMO 2013;27:221-34.
Open. 2023;8:100745. doi: 10.1007/s10822-013-9644-8
doi: 10.1016/j.esmoop.2022.100745 28. Schrödinger Release 2023-3: LigPre. New York,: Schrödinger,
17. Naim N, Moukheiber S, Daou S, et al. KRAS-G12C covalent LLC; 2023.
inhibitors: A game changer in the scene of cancer therapies. 29. Shelley JC, Cholleti A, Frye LL, et al. Epik: A software
Crit Rev Oncol Hematol. 2021;168:103524. program for pK(a) prediction and protonation state
doi: 10.1016/j.critrevonc.2021.103524 generation for drug-like molecules. J Comput Aided Mol
Des. 2007;21:681-691.
18. Molina-Arcas M, Samani A, Downward J. Drugging the
undruggable: Advances on RAS targeting in cancer. Genes doi: 10.1007/s10822-007-9133-z
(Basel). 2021;12:899. 30. Canon J, Rex K, Saiki AY, et al. The clinical KRAS(G12C)
doi: 10.3390/genes12060899 inhibitor AMG 510 drives Anti-tumour immunity. Nature.
2019;575:217-223.
19. Skoulidis F, Li BT, Dy GK, et al. Sotorasib for lung cancers
with KRAS p.G12C mutation. N Engl J Med. 2021;384: doi: 10.1038/s41586-019-1694-1
2371-2381. 31. Schrödinger Release 2023-3: Protein Preparation Wizard;
doi: 10.1056/nejmoa2103695 Epik. New York: Schrödinger, LLC; 2023.
20. Lanman BA, Parsons AT. Sotorasib (LUMAKRAS), an 32. Roos K, Wu C, Damm W, et al. OPLS3e: Extending force
ırreversible covalent Inhibitor of KRAS G12C . İn: Current field coverage for drug-like small molecules. J Chem Theory
Drug Synthesis. United States: Wiley; 2022. p. 183-199. Comput. 2019;15:1863-1874.
doi: 10.1021/acs.jctc.8b01026
doi: 10.1002/9781119847281.ch10
33. Zhu K, Borrelli KW, Greenwood JR, et al. Docking covalent
21. Saleh K, Kordahi M, Felefly T, et al. KRAS-targeted
therapies in advanced solid cancers: Drug the undruggable? inhibitors: A parameter free approach to pose prediction
Pharmacogenomics. 2021;22:587-90. and scoring. J Chem Inf Model. 2014;54:1932-1940.
doi: 10.1021/ci500118s
doi: 10.2217/pgs-2021-0045
34. Friesner RA, Banks JL, Murphy RB, et al. Glide: A New
22. Kim HJ, Lee HN, Jeong MS, et al. Oncogenic KRAS: Signaling Approach for rapid, accurate docking and scoring. 1.
and drug resistance. Cancers (Basel). 2021;13:5599.
Method and assessment of docking accuracy. J Med Chem.
doi: 10.3390/cancers13225599 2004;47:1739-1749.
23. Oyedele AQK, Ogunlana AT, Boyenle ID, et al. doi: 10.1021/jm0306430

Volume 4 Issue 1 (2025) 91 doi: 10.36922/td.5163